Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study or primitive neuroectodermal tumour [PNET] ), which opened in 1989. Examination of the ET-2 and MMT-89 databases in 1991 revealed 119 surviving patients who had completed treatment with ifosfamide-containing schedules at the 11 participating centres. Of these, 91 (77%) were studied, but 17 (14%) were no longer available for study due to death or disease progression. Only 11 (9%) potentially available patients were not studied. An additional 57 patients treated with ifosfamide using protocols other than ET-2 or MMT-89 were studied at four of the participating centres. Twenty of these patients have been included in a previous single centre report . In total, therefore, 148 patients were studied. All but one received ifosfamide at their initial presentation, the other patient at first relapse.
Between 1992 and 1994 each patient was studied once prospectively at a median of 6 (range 1-47) months after completion of chemotherapy. Their median age at commencement of ifosfamide treatment was 8.1 (range 0.1-25.2) years; 87 were male. Only one was over 20 years of age.
The patients had been treated for RMS (65 patients), ES of bone (59), other STS (16), extraosseous ES or PNET (seven), or osteosarcoma (one). At commencement of ifosfamide treatment, one patient with lower urinary tract obstruction had a raised serum creatinine concentration; no other patient had clinical evidence of abnormal renal function (raised serum creatinine and/or glomerular filtration rate [GFR] < 60 ml/min/1.73 m 2 ). Although no patient had undergone a nephrectomy, and none had renal infiltration by tumour, nine (including the child described above) had urinary tract obstruction due to tumour at initial diagnosis of their malignancy.
Treatment
Ifosfamide was given intravenously (i.v.) by continuous infusion (6-9 g/m 2 course -1 over 48-72 h) in 93 patients (including 12 in whom a minority of courses were given by short (1-3 h) infusions); by short (3 h) infusions (3 g/m 2 ) on 3 successive days per course (i.e. 9 g/m 3 course -1 ) in 53 (including two in whom a minority of courses were given by continuous infusion); or by both schedules (each being used for an equal number of courses) in two.
The median total ifosfamide dose was 62.0 (6.1-165.0) g/m 2 , given over a median of 8 (1-18) courses at 3-week intervals. All patients received continuous i.v. hydration fluid as specified by the treatment protocols, and all received a continuous i.v. infusion of mesna, with additional boluses in nine. Radiotherapy was given to a treatment volume that included renal tissue in four patients, whilst other potentially nephrotoxic chemotherapy or i.v. supportive treatment was given to 121 patients; three received cisplatin, 107 aminoglycoside antibiotics, 44 vancomycin, 38 acyclovir and 24 standard amphotericin B.
Investigation and grading of nephrotoxicity
The study protocol was approved by the Joint Ethics Committee of Newcastle Health Authority and the University of Newcastle upon Tyne, and allowed assessment of glomerular, proximal and distal renal tubular function (Skinner et al, 1991) .
Glomerular function
GFR and serum creatinine concentration were measured. The plasma clearance of 51 chromium-labelled ethylenediaminetetraacetic acid ( 51 Cr-EDTA) was recommended as the method of choice to determine GFR, and was used in 116 patients. GFR was measured from the plasma clearance of 99m technetium-labelled diethylenetriaminepentaacetic acid ( 99m Tc-DTPA) in a further seven patients.
Proximal tubular function
Concentrations of electrolytes, creatinine, calcium, magnesium, PO 4 and glucose were measured in corresponding serum and urine samples. The HCO 3 was also measured. The fractional excretions of sodium, potassium, calcium, magnesium, phosphate (FEp), glucose (FEg) and urate, and the renal tubular threshold for phosphate (Tm p /GFR) were calculated using standard formulae (Skinner et al, 1991) . The fractional excretion of a substance is the percentage of the filtered load at the glomerulus that is subsequently excreted in the urine; an abnormally high fractional excretion indicates reduced tubular reabsorption. Except for FEg, a fractional excretion was considered abnormal only when elevated in the presence of a reduced serum concentration. The Tm p /GFR provides a measure of tubular phosphate reabsorption, being reduced in the presence of impaired reabsorption.
Distal tubular function
The early morning urine pH and osmolality (EMUO) were measured in the first sample voided on the day of study. Achievement of a pH of ≤ 5.4 was taken to demonstrate normal urinary acidification, and an EMUO of ≥ 600 mOsm/kg to indicate adequate urinary concentration. However, failure to reach these values in a single early morning urine sample was not considered proof of abnormal distal tubular function.
General aspects of renal function
The urinary concentrations of albumin and total protein were measured, and expressed as ratios to the simultaneous urine creatinine concentration. Systolic blood pressure was also measured.
Nephrotoxicity grading
This was performed using a previously described system (Skinner et al, 1993) , which comprises measurement and scoring of GFR, Tm p /GFR, serum HCO 3 and EMUO. These measures were selected to give an overall measure of clinically important nephrotoxicity due to ifosfamide, reflecting those aspects of toxicity with the potential to cause morbidity or require chronic treatment. Each was scored on a 0-4 scale, with 0 representing no, 1 mild, 2-3 moderate and 4 severe toxicity within each individual aspect of renal damage. The individual scores are summated to give a 'nephrotoxicity score', potentially ranging from 0 to 16 (Table 1) . Other individual measures of nephrotoxicity were also graded on a 0-4 scale, and categorized as showing either no/mild toxicity (grades 0 and 1; defined as serum sodium concentration ≥ 121 mmol/l in children < 12 months age or ≥ 126 mmol/l for ≥ 1 year age, serum potassium ≥ 3.0 mmol/l, serum calcium ≥ 1.95 mmol/l, and serum magnesium ≥ 0.60 mmol/l for < 2 years age or ≥ 0.55 mmol/l for ≥ 2 years age), or moderate/ severe toxicity (grades 2-4; defined as serum sodium, potassium, calcium or magnesium concentrations lower than those listed above for grades 0 and 1).
Normal ranges
The normal ranges for serum biochemistry and fractional excretions were derived from investigation of 105 otherwise healthy children and adolescents (aged 0.1-16.6 years, 27 male) attending the Royal Victoria Infirmary, Newcastle upon Tyne for investigation of a proven urinary tract infection (treated at least 1 month previously), in whom clinical examination, renal and urinary tract investigations and imaging proved to be normal (Table 2) .
Previously outlined normal ranges were used for age-or sexdependent measures of toxicity, including biochemical variables (serum concentrations of creatinine, bicarbonate, phosphate and magnesium; and Tm p /GFR) (Skinner et al, 1991) , and systolic blood pressure (Children, 1987) (Table 2) . ) (i.e. evaluating glomerular dysfunction); Tm p /GFR = renal tubular threshold for phosphate (mmol/l) (i.e. evaluating phosphaturia); HCO 3 = blood bicarbonate concentration (mmol/l) (i.e. evaluating acidosis); EMUO = early morning urine osmolality (mOsm/kg) (i.e. evaluating impairment of urine concentration); HR = hypophosphataemic rickets, HCMA = hyperchloraemic metabolic acidosis (i.e. renal tubular acidosis), NDI = nephrogenic diabetes insipidus defined by clinical symptoms, signs, biochemical findings, and for HR, radiological abnormalities; DDAVP = DDAVP (desmopressin) test -a normal response is defined by a urine osmolality ≥ 800 mOsm/kg. (Clayton et al, 1980; Brodehl et al, 1982; Skinner et al, 1991) . **See text (Methods) (Skinner et al, 1991) . Unless otherwise stated, normal ranges are derived from investigation of 105 healthy children aged 0.1-16.6 years (see text). Some published normal ranges were used, as listed below: # Barratt, (1974) 
Statistical analysis
The normality or otherwise of variables was examined using the skewness and kurtosis tests. Multiple linear regression analysis was used to evaluate total ifosfamide dose, age at start of treatment, sex, ifosfamide schedule (short infusion or continuous infusion) and exposure to other potential nephrotoxins, namely aminoglycosides, vancomycin, acyclovir or amphotericin B (categorized as treatment at any time, or not, with each of these drugs) as predictors for nephrotoxicity measured by GFR, serum PO 4 and HCO 3 and Tm p /GFR. Initially all predictor variables were included in multiple regression in a backward stepwise procedure and the least significant variables (P > 0.2) were rejected. Only total dose was found consistently to be significant (see Results); therefore univariate linear regression was performed with total dose only.
The nephrotoxicity score had a highly skewed distribution. Therefore, it was categorized as either none/mild (score 0-3) or moderate/severe (score ≥ 4), and stepwise logistic regression analysis was performed in which the 8 independent variables (dose, age, sex, schedule, and exposure to aminoglycosides, vancomycin, acyclovir or amphotericin B) were used to predict nephrotoxicity score. The above analyses were repeated after exclusion of 16 patients with other major risk factors for the development of nephrotoxicity (urinary tract obstruction at commencement of ifosfamide treatment, radiotherapy to renal tissue, cisplatin treatment). The absolute values of the individual elements of nephrotoxicity (e.g. GFR) in patients in whom the nephrotoxicity score could be calculated (i.e. patients with evaluable GFR, Tm p /GFR, serum HCO 3 and EMUO) were compared with those in patients in whom the score could not be calculated, using unpaired t-tests for each variable. Analyses were performed using STATA statistical software (StataCorp, 1997) .
RESULTS
Those continuous measures of nephrotoxicity described below had an approximately normal distribution. Nephrotoxicity was observed in a substantial proportion of patients (Table 2) , although considerable inter-individual variability was evident (Figures  1-2 ).
Glomerular function
GFR was below 90 ml/min/1.73 m 2 in 61 of 123 evaluable patients (50%), and below 60 ml/min/1.73 m 2 (i.e. grade 2-4 toxicity) in 11 (9%). The 51 Cr-EDTA plasma clearance technique was used in 58 of these and the 99m Tc-DTPA plasma clearance method in three. The serum creatinine concentration was elevated in 63 of 146 patients (43%). A statistically significant fall in GFR was observed in 67 patients in whom it was measured (using the same method) both at diagnosis and after completion of treatment (mean [95% confidence limits] fall 35.1 [22.1-47.9] ml/min/ 1.73 m 2 ; paired t-test, t = 8.96, P < 0.001).
UKCCSG study of ifosfamide nephrotoxicity 1639
British Journal of Cancer (2000) 82 ( Only 19 of these 103 children (18%) had a high FEp. Excessive urinary excretion of other electrolytes was present in a smaller proportion of patients, with high fractional excretions of potassium in eight of 100 evaluable children, and of sodium in two of 103 (2%). The commonest urinary abnormality was glycosuria, shown by a high FEg in 52 of 59 evaluable patients (88%). Only three of 52 evaluable patients (6%) had a high fractional excretion of urate.
Distal tubular function
The early morning urine was adequately acidified (pH ≤ 5.4) in only 28 of 108 evaluable patients (26%), and concentrated (EMUO ≥ 600 mOsm/kg) in 78 of 123 (63%).
General aspects of renal function
Although only three of 67 evaluable patients (4%) had an elevated urine protein:creatinine concentration ratio, six of 15 (40%) had a high urine albumin:creatinine concentration ratio. Six of 127 evaluable patients (5%) had severe systolic hypertension; all other patients were normotensive.
The majority of patients with glomerular toxicity also had evidence of tubular impairment. Of 44 fully evaluable patients with GFR grade ≥ 1 (i.e. mild or greater toxicity), only 15 (34%) had grade 0 Tm p /GFR and HCO 3 . More strikingly, nearly all children with tubular toxicity had glomerular damage. Of 40 fully evaluable patients with grade ≥ 1 Tm p /GFR and HCO 3 , only one (3%) had grade 0 GFR.
Nephrotoxicity grading
The nephrotoxicity score was fully evaluable (i.e. GFR, Tm p /GFR, HCO 3 and EMUO all evaluable) in 76 patients. Of these, 17 (22%) had no, 38 (50%) mild, 15 (20%) moderate and six (8%) severe nephrotoxicity, using the definitions shown in Table 1 . No significant difference was seen in the severity of nephrotoxicity between these patients and the other 72 in whom the nephrotoxicity score was not fully evaluable. No child had grade 4 toxicity for GFR, but ten of 103 (10%) had grade 4 toxicity for Tm p /GFR, one of 95 (1%) for HCO 3 , and five of 123 (4%) for EMUO.
Risk factors
GFR, serum PO 4 , serum HCO 3 and Tm p /GFR Multiple regression analysis revealed that only total dose exerted a consistent significant effect (P < 0.05) on GFR, serum PO 4 and HCO 3 and Tm p /GFR. Univariate linear regression analysis revealed statistically significant and clinically important correlations between total ifosfamide dose and GFR (P = 0.006) (Figure  1 ), serum PO 4 (P < 0.001) and HCO 3 (P < 0.001), and Tm p /GFR (P < 0.001) (Figure 2) (Table 3 ). Higher doses were associated with Table 4 ). The other predictor variables studied in the multivariate analysis had no independent effect, with the exceptions of relationships between younger age at treatment and lower serum HCO 3 (P < 0.001), acyclovir exposure and lower Tm p /GFR (P = 0.02), and amphotericin B exposure and lower serum PO 4 (P = 0.049) ( Table 3) .
Nephrotoxicity score
Multiple logistic regression revealed that only total ifosfamide dose had a significant predictive influence (P = 0.001) on nephrotoxicity score (none/mild vs moderate/severe); other potential risk factors had no significant effect (P > 0.1 in all cases). An increase in ifosfamide dose of 50 g/m 2 increased the risk of moderate/severe (compared to no/mild) nephrotoxicity by an odds ratio of 6.8 (95% confidence limits 2.7-16.9). The importance of ifosfamide dose in determining the likelihood of no, mild, moderate or severe nephrotoxicity is illustrated in Figure 3 .
Exclusion of the 16 patients with other major risk factors for the development of nephrotoxicity did not change the outcome of these analyses -total dose remained the only consistently significant predictor of nephrotoxicity.
DISCUSSION
Although early studies failed to reveal any evidence of nephrotoxicity in children receiving ifosfamide (de Kraker and Voute, 1984; Gasparini, 1986; Biron et al, 1987; Kellie et al, 1988; Demeocq et al, 1989) , subsequent reports described a characteristic pattern of proximal renal tubular damage, often accompanied by glomerular and sometimes by distal tubular impairment (Smeitink et al, 1988; Burk et al, 1990; Skinner et al, 1990; Pratt et al, 1991; Suarez et al, 1991; Caron et al, 1992; Shore et al, 1992; De Schepper et al, 1993; Arndt et al, 1994; Ashraf et al, 1994) . Such toxicity persisted long after discontinuation of ifosfamide treatment in many patients, often presenting with clinical manifestations due to the Fanconi syndrome (Skinner et al, 1993) . It is now clear that there is much inter-individual variability in the onset, nature and severity of renal toxicity due to ifosfamide. Many children suffer little or no renal toxicity, but a few are severely affected (Smeitink et al, 1988; Skinner et al, 1990 Skinner et al, , 1993 . Acute tubular toxicity may follow the first course of treatment (Heney et al, 1989; Devalck et al, 1991) , or chronic glomerular and tubular damage may present many months after completion of ifosfamide (Moncrieff and Foot, 1989; De Schepper et al, 1991; Suarez et al, 1991; Caron et al, 1992) .
The reported incidence of severe chronic nephrotoxicity in children has varied widely from 1.4% (Pratt et al, 1991) to about 30% (De Schepper et al, 1993) , probably depending on the distribution of risk factors amongst different patient groups and on the sensitivity of the methods used to detect renal damage. The commonest clinical sequelae of ifosfamide nephrotoxicity include hypophosphatemia, which may lead to rickets (Moncrieff and Foot, 1989; Burk et al, 1990; Skinner et al, 1990; De Schepper et al, 1991; Pratt et al, 1991; Suarez et al, 1991; De Schepper et al, 1993) , and renal tubular acidosis (Heney et al, 1989; Suarez et al, 1991) , both of which may impair growth (De Schepper et al, 1991) . Nephrogenic diabetes insipidus may occur (Smeitink et al, 1988; Skinner et al, 1990) .
The degree of reversibility of ifosfamide nephrotoxicity remains uncertain. Although partial improvement may occur, including resolution of rickets without specific treatment (Van Gool et al, 1992) and improvement in biochemical abnormalities in some children (Suarez et al, 1991; Caron et al, 1992) , there is only one published description of complete recovery from severe, chronic glomerular and tubular impairment in children (Ashraf et al, 1997) . Indeed, there is evidence that glomerular (Burk et al, 1990; Prasad et al, 1996) and tubular (Caron et al, 1992) toxicity may progress over a period of months or years following completion of ifosfamide treatment.
Several risk factors for the development of nephrotoxicity after ifosfamide have been suggested, including age, the total dose of ifosfamide received, the method of drug administration, previous or concurrent treatment with cisplatin, prior nephrectomy and the presence of pre-existing renal impairment or infiltration by tumour (Skinner et al, 1993) . Furthermore, quantitative inter-patient variability in ifosfamide metabolism may determine individual risk (Skinner et al, 1993) .
Although ifosfamide nephrotoxicity may occur at any age (Skinner et al, 1993) , most published reports of severe toxicity have been in young children, who may be more susceptible to proximal tubular toxicity, (Suarez et al, 1991; Caron et al, 1992; Shore et al, 1992; De Schepper et al, 1993; Skinner et al, 1993; Raney et al, 1994) , due to a combination of anatomical, biochemical and physiological factors (Fetterman et al, 1965) . Although extensive renal damage has occurred after total ifosfamide doses of between 12 and 60 g/m 2 (Smeitink et al, 1988; Heney et al, 1989; Moncrieff and Foot, 1989; Burk et al, 1990; Devalck et al, 1991) , several authors have suggested that children receiving higher cumulative doses (> 60 or > 72 g/m 2 ) have a greater risk of nephrotoxicity (Bisogno et al, 1993; De Schepper et al, 1993; Skinner et al, 1993; Raney et al, 1994) .
Despite documented variability in ifosfamide metabolism with different schedules, no published evidence is yet available which shows convincingly that any one administration regiment of ifosfamide and mesna is superior in terms of improved efficacy or reduced toxicity (Skinner et al, 1993) . Some studies have found an increased incidence of severe ifosfamide nephrotoxicity in patients who have also received cisplatin (Moncrieff and Foot, 1989; Pratt et al, 1991; Shore et al, 1992; Rossi et al, 1994) or who had previously undergone unilateral nephrectomy (Burk et al, 1990; Rossi et al, 1994) . Furthermore, there are several case reports of severe renal damage after ifosfamide treatment in patients with renal infiltration by tumour (Bremner et al, 1974; Holoye et al, 1982) , or those with pre-existing renal impairment (Wheeler et al, 1986; Davies et al, 1989 ), but it is not known whether the overall incidence of nephrotoxicity is increased in these patients. There is still much uncertainty about role of each of these risk factors, especially age, dose and cisplatin treatment, but ascertainment of the most important might enable prediction and careful monitoring of 'high risk' patients or. A major aim of this study was therefore to clarify which of the above risk factors was most important in a large group of children and adolescents receiving ifosfamide in standard treatment protocols in the UK.
The commonest abnormal finding was of proximal tubular toxicity in association with glomerular impairment. Fewer patients had isolated glomerular, and very few isolated tubular, damage. Additional biochemical abnormalities most likely to be due to proximal tubular toxicity were seen in a minority of patients, but the magnitude of these latter abnormalities was considerably less than that of the hypophosphataemia and acidosis.
The finding that GFR was reduced in 50% of patients demonstrates that glomerular impairment is very common when accurate measurements (e.g. radioisotopic plasma clearance methods) are used. Although reports of chronic renal failure are very rare (Sangster et al, 1984) , this frequency of subclinical glomerular damage leads to concern about the future prognosis for renal function in some of these patients. The glomerulotoxic nature of ifosfamide was shown clearly by the mean fall of 35 ml/min/1.73 m 2 in the 66 patients in whom GFR was measured before and after chemotherapy.
The system of nephrotoxicity grading (Skinner et al, 1993 ) employed in this study provided an objective overall measure of the severity of clinically relevant nephrotoxicity, in contrast to the more subjective score proposed previously by Caron et al (1992) . The demonstration that only 22% of 76 fully evaluable patients had no nephrotoxicity, and that 28% had moderate or severe clinically relevant toxicity, is therefore particularly worrying. It might be argued that patients with severe toxicity were more likely to be entered into this study, and to be evaluated fully. However, this is unlikely to have been the case since no selection bias within centres was apparent with respect to patient entry. In total, 91% of the 119 potentially eligible patients identified at the start of the study were either studied or excluded due to death or progressive disease. Furthermore, there was no significant difference in the severity of proximal tubular toxicity between the 76 patients with fully evaluable nephrotoxicity scores and the 72 without.
The analysis of risk factors for the development of ifosfamide nephrotoxicity in this population of patients, none of whom had undergone nephrectomy and only three of whom had received cisplatin, has demonstrated clearly that total dose is the most important risk factor. This is of great practical importance because in many countries ifosfamide is seldom used in combination with cisplatin or in patients who have undergone unilateral nephrectomy. Therefore total ifosfamide dose is probably more generally relevant as a major risk factor than prior or concurrent cisplatin treatment and nephrectomy. Although it is clear from Figures 1 and 2 that the considerable inter-patient variability in the severity of nephrotoxicity, even between patients receiving similar doses, prevents definition of an entirely 'safe' dose limit, Figure 3 demonstrates that no patients receiving < 84 g/m 2 suffered severe, and only 20% moderate, nephrotoxicity; whilst of those receiving > 119 g/m 2 , 33% suffered severe and 40% moderate nephrotoxicity. Clearly, clinically significant nephrotoxicity is relatively infrequent below 84 g/m 2 but unacceptably common above 119 g/m 2 .
Another important finding is that age is not a major independent risk factor. The relevance of the statistically significant relationship between younger age and lower serum HCO 3 is uncertain since healthy infants have lower serum HCO 3 concentrations (Skinner et al, 1991) . However, caution is still necessary in younger patients, in whom the consequences of nephrotoxicity, including growth impairment, may be greater. This is the largest published study of ifosfamide nephrotoxicity in which investigations have been performed prospectively. However, a few potential criticisms of the study may be made. In particular, the multi-centre design might have led to bias in patient selection. However, there was no evidence of such bias, and a consistent investigatory protocol was used in all centres, incorporating well established and straightforward clinical investigations. Some of these investigations have normal ranges that vary with age, but this was accounted for in the analysis of the frequency of toxicity. It is theoretically possible that the higher normal values of serum PO 4 and of Tm p /GFR in younger children may have obscured the importance of younger age as a risk factor for this aspect of proximal tubular toxicity. However, there was no other suggestion that age was a significant predictor of nephrotoxicity, even with measures of renal function that do not vary significantly over the age range studied (e.g. GFR, which is stable after the age of 2 years).
Although ifosfamide administration schedule was included as a predictor in the multiple regression model, this analysis may not have been able to distinguish any potential independent effect of schedule from that of the total ifosfamide dose received in view of the close relationship between the schedule used and total dose received. However, inspection of Figures 1 and 2 does not suggest that schedule has any important independent influence. The majority of patients studied had been exposed to other potential nephrotoxic insults. Exclusion of 16 patients with the most important potential risk factors (urinary tract obstruction, renal radiotherapy, cisplatin) did not alter the results, and analysis of the possible importance of exposure to other nephrotoxic drugs (aminoglycosides, vancomycin, acyclovir, amphotericin B) did not suggest any consistent pattern of increased nephrotoxicity. However, exposure to these drugs was only recorded as present or absent, so interpretation of their possible additive effects in ifosfamide nephrotoxicity is limited.
The cross-sectional nature of the study is unlikely to have biased the results significantly since there is no published evidence of consistent important changes in the severity of chronic ifosfamide nephrotoxicity with time after completion of treatment, and any such changes would have been highly unlikely to produce systematically a spurious dose effect of the magnitude observed in this study. In any case the occurrence of chronic nephrotoxicity at any time after completion of treatment is of concern.
The results of this study suggest that future strategies to prevent ifosfamide nephrotoxicity in children and adolescents should be centred around dose limitation, but also imply that this approach, whilst reducing the frequency of clinically significant nephrotoxicity, will not prevent all cases. It is possible that some of the interpatient variability in the severity of toxicity reflects corresponding differences between individuals in the pharmacokinetics and metabolism of ifosfamide, but this remains unproven (Boddy et al, 1996) . Identification of such a relationship and its use to enable prediction of the risk of subsequent nephrotoxicity clearly would be of great value. An alternative approach of using the occurrence and magnitude of early subclinical nephrotoxicity to enable prediction of subsequent chronic toxicity is under investigation (Skinner et al, 1994) . Although it appears unlikely that different ifosfamide schedules are associated with different risks of toxicity, this issue should be addressed in a comparative study that includes endpoints of efficacy as well as toxicity.
In conclusion, this large and comprehensive prospective study has shown that moderate and severe nephrotoxicity are common after ifosfamide treatment in children and adolescents, affecting 28% of patients. Multivariate analysis revealed that total ifosfamide dose was the only significant risk factor for the development of toxicity in this group of patients, only three of whom received cisplatin. Although it was not possible to specify a clinically realistic total dose below which toxicity was never observed, use of doses below 84 g/m 2 will reduce the frequency of clinically significant nephrotoxicity.
